ArticleChemSusChem2026
Photobiocatalytic Linear Deracemization of β-Hydroxynitriles.
Article in ChemSusChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A photobiocatalytic strategy for the linear deracemization of β-hydroxynitriles is presented. This method consists of a two-step process, beginning with the oxidation of the corresponding alcohol racemate (250 mM) using tetrabutylammonium decatungstate (TBADT, 2.5-5.0 mol%) under 390 nm light irradiation in acetonitrile. The second step involves an asymmetric biocatalytic reduction, carried out sequentially by addition of the required reagents with or without solvent evaporation depending on the selected alcohol dehydrogenase (ADH) enzyme and its tolerance to the organic solvent. Under the resulting aqueous conditions (25-75 mM ketone intermediate), the enzymes exhibited high selectivity, enabling access to a series of optically active β-hydroxynitriles, predominantly with excellent optical purities, leading to nine pairs of enantiomers in 88 to >99% ee. The integration of two sustainable technologies, photo- and biocatalysis, provides a straightforward route to chiral β-hydroxynitriles. In addition, sunlight-driven applicability and scalability are demonstrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.